Infarmed is currently evaluating the potential widespread hospital use of a new cancer drug after previously denying a special authorisation request for a 35-year-old patient.
State evaluates whether to pay for new cancer drug
Sunday, 15 March 2026RSS
Context & Explainers
Infarmed (Autoridade Nacional do Medicamento e Produtos de Saúde) is Portugal’s national regulator for medicines and health products that approves drugs, monitors safety and enforces rules on pricing and reimbursement. In 2025 it approved 928 new medicines — 79% were generics, 38 were designated essential and 236 were national products — which affects which medicines are available and how much they cost at pharmacies.
AI Summary AvailableHealth authority evaluates funding for new brain cancer drugRead the synthesized summary with context and explainers
View full article on Correio da Manhã
